期刊
DERMATOLOGIC THERAPY
卷 35, 期 3, 页码 -出版社
WILEY-HINDAWI
DOI: 10.1111/dth.15284
关键词
adalimumab; immune response; methotrexate; microbiology; psoriasis
类别
资金
- Novo Nordic Foundation
Methotrexate has minimal effect on cytokine responses, while adalimumab affects a wide range of cytokines involved in immune defense. The cytokine levels in patients receiving long-term adalimumab treatment are almost equivalent to those receiving short-term treatment.
Patients with psoriasis are commonly treated with methotrexate or biologics. We examined the immune response in a whole blood assay (TruCulture (R)) to assess the effect of methotrexate and adalimumab. Twenty patients with psoriasis were included and cytokine levels following stimulation with LPS, R848, HKCA, PolyIC, or a blank were investigated before and after 3-6 months of treatment with methotrexate or adalimumab and in patients who had received adalimumab >5 years. Methotrexate only induced minor changes in the cytokine responses, whereas adalimumab affected a wide range of cytokines important for the immune defense towards microorganisms. In the long-term adalimumab treated group, the cytokine levels were almost equivalent to the short-term adalimumab-treated group. Overall, methotrexate was not associated with cytokine suppression. Short and long-term treatment with adalimumab lowered multiple cytokines involved in the immune defense equally emphasizing the need to continuously be aware of the risk of infections in these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据